Clinical trials: Multiple Dose
Metabolic Dysfunction-Associated Steatohepatitis
A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH
This Phase 1 trial will explore the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses of INI-822 in healthy volunteers in Parts A, B, D and F and in participants with a…
- Trial name
- NCT05945537
- Testing
- INI-822 (A)
- Where
- 11 sites in Australia
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Inipharm Australia Pty Ltd
Healthy
A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects
This is an open-label study investigating the relationship between SEP-228432 and SEP-228431 (the active metabolite of SEP-228432) plasma concentrations, SERT occupancy, and DAT occupancy, both measured by SPECT imaging.
- Trial name
- NCT01531972
- Testing
- SEP-228432
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
Autoimmune Diseases
A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)
This is a phase 1 study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of VIS171 in healthy participants and in participants with autoimmune disease(s).
- Trial name
- NCT05418101
- Testing
- VIS171
- Where
- 10 sites in Bulgaria, Germany and 3 more
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy Subjects
A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects
This will be an investigator- and subject-blinded (sponsor open), randomized, placebo controlled, sequential, ascending, multiple oral dose study, with 5 planned cohorts (optional sixth and seventh cohorts).
- Trial name
- NCT03230383
- Testing
- PF-06865571
- Where
- 2 sites in United States, Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Elderly
MAD Study of NX210c
This study will investigate the safety and tolerability of multiple intravenous infusions of NX210c with two ascending doses as well as NX210c pharmacokinetics (PK), and pharmacodynamics (PD) effects in healthy elderly subjects.
- Trial name
- CHDR2235 (NCT05827653)
- Testing
- NX210c
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Axoltis Pharma
Healthy Volunteers
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR741 in Healthy Volunteers
The purpose of this study is to assess the safety and tolerability of single and multiple intravenous doses of SPR741 when administered to healthy adult volunteers.
- Trial name
- NCT03022175
- Testing
- SPR741
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Spero Therapeutics
Pulmonary Arterial Hypertension
A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses
Sitaxsentan has a low drug-drug interaction potential and it did not have a clinically relevant effect on pharmacokinetics of sildenafil (a CYP3A sensitive substrate and PDE5 inhibitor).
- Trial name
- NCT01244620
- Testing
- sitaxentan, tadalafil, sitaxsentan
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects
This is a Phase I, randomized, subject-blinded, placebo controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD),and food effect (FE) of HSK39297 following (1) a single ascending dose (part…
- Trial name
- NCT06350279
- Testing
- HSK39297
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Healthy
An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of Two Controlled Release Pregabalin Tablets As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule
The purpose of this study is to 1) evaluate the extent of absorption of multiple doses of two pregabalin controlled release tablets as compared to multiple doses of the pregabalin immediate release capsule, 2) evaluate the…
- Trial name
- NCT01202422
- Testing
- Pregabalin controlled release, 165 mg, Pregabalin controlled release, 330 mg, Pregabalin immediate release, 150 mg
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Part I (SAD) - Healthy Participants, Part II (MAD) - Chronic Obstructive Pulmonary Disease
Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants
This is a Phase 1, randomised, blinded, placebo controlled, study designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity response to single and multiple doses of MEDI3506.
- Conditions
- Part I (SAD) - Healthy Participants, Part II (MAD) - Chronic Obstructive Pulmonary Disease, Part III (J-SD) - Healthy Japanese Participants
- Trial name
- NCT03096795
- Testing
- MEDI3506
- Where
- 2 sites in United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza, Human
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older
Study to evaluate the safety and immunogenicity of H7N9 antigen in combination with full or half doses of AS03 adjuvant system in healthy adults.
- Trial name
- NCT04789577
- Testing
- FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3
- Where
- 8 sites in United States
- Volunteers
- 833 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Male Volunteers
Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802
The purpose of this study is to evaluate the drug-drug interaction between LGEV1801 and LGEV1802 in healthy male volunteers.
- Trial name
- NCT03532854
- Testing
- Valsartan, Ezetimibe/Rosuvastatin
- Where
- South Korea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- LG Chem
Healthy
A Study in Healthy Japanese Men to Test How Different Doses of BI 690517 Are Taken Up in the Body and How Well They Are Tolerated
The primary objective of the trial is to investigate the safety and tolerability of BI 690517 in healthy Japanese male subjects following oral administration of multiple rising doses over 14 days.
- Trial name
- NCT03608072
- Testing
- BI 690517
- Where
- Japan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy Volunteers
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of single and multiple intravenous doses of SPR206 when administered to healthy adult volunteers.
- Trial name
- NCT03792308
- Testing
- SPR206
- Where
- Australia
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Spero Therapeutics
Autism Spectrum Disorder
The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan
This is a multi-center, non-randomized, open-label, parallel group, multiple-dose study to assess the pharmacokinetic, safety, and tolerability of balovaptan in male and female subjects with moderate hepatic impairment compared…
- Trial name
- NCT03912350
- Testing
- Balovaptan
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Neurologic Diseases, General
Intranasal Administration of Dodecyl Creatine Ester (CBT101) in Healthy Male Subjects
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled study to Evaluate the Safety, Tolerability,and Pharmacokinetics of Single and Multiple Ascending Doses of CBT101 given intranasally in Healthy Male Subjects.
- Trial name
- CBT101 (NCT07050316)
- Testing
- CBT101
- Where
- France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Ceres Brain Therapeutics
Healthy Volunteers
A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants
This study will evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of ATH-399A in healthy adults and also evaluate the effect of food on ATH-399A in order to develop mechanism-based and/or…
- Trial name
- NCT06088784
- Testing
- ATH-399A, ATH-399A 10 mg, 5 mg ATH-399A capsule
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- HanAll BioPharma Co., Ltd.
Overweight,Obesity
Dose-escalation and Food Effect Study of ZT006 in Healthy, Overweight and Obese Participants
ZT006 is an oral, long-acting glucagon-like peptide-1. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZT006 in healthy, overweight and obese participants.
- Trial name
- NCT07307638
- Testing
- ZT006
- Where
- China
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Healthy Volunteers
Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023
This is a randomized, double-blind, placebo-controlled, multiple ascending dose study conducted at one study center in the United States.
- Trial name
- NCT03542435
- Testing
- SXC-2023
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Promentis Pharmaceuticals, Inc.
Drug Interactions
Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women
Physicians might be concerned that Adempas may have a metabolic interaction with oral contraceptives (OC) that could decrease the contraceptive efficacy of the OC.
- Trial name
- NCT02159326
- Testing
- Microgynon, Riociguat (Adempas,BAY63-2521)
- Where
- Germany
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.